The FDA-approved ipilimumab, a CTLA-4 blocking antibody, has shown success in various malignancies by targeting the PD-1 pathway, highlighting the significance of the B7-CD28 family in tumor immunotherapy (29). The gene discussed is CTLA4; the disease is neoplasm.